ProCE Banner Activity

CE / CME

Identification and Management of Tardive Dyskinesia

Video

Tardive dyskinesia (TD) can be observed in patients receiving long-term treatment with dopamine receptor blocking agents. As the indications for these agents have expanded, TD is becoming more prevalent.  In this activity, an expert reviews TD including risk factors, prevention, and treatment. 

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: January 19, 2023

Expiration: January 18, 2024

No longer available for credit.
Begin Activity

Share

Faculty

Amber Hoberg

Amber Hoberg, PMHNP

Nurse Practitioner
MorningStar Family Medicine
Floresville, Texas

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Neurocrine Biosciences, Inc.

Target Audience

NPs and PAs

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders

  • Describe the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Jonathan M. Meyer, MD, consultant: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America Inc., Sunovion Pharmaceuticals, Teva Pharmaceuticals.

Amber Hoberg, PMHNP, consultant: Acadia, Avanir, BioXcel, Intracellular Therapies, Neurocrine, Teva.

Amanda Zimmerman, PA-C, consultant/advisor/speaker: Averitas; researcher: Collegium.

The planners and content reviewers from Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose except Amber Hoberg, PMHNP and Amanda Zimmerman, PA-C as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Format

This program has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

 

AAPA Credit Designation
Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 18, 2024. PAs should only claim credit commensurate with the extent of their participation.

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.